Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ioflupane I-123

FDA-approved product (solution, intravenous), marketed as Datscan, Ioflupane I-123.

Registered studies
36
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ioflupane I-123
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Abnormality of movement
  • Alzheimer disease
  • Computed tomography
  • Dementia
  • Lewy body dementia
  • Movement disorder
  • Multiple system atrophy
  • Neuroimaging measurement
  • Parkinson disease
  • Radiologic finding

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Iodine (123i) compounds
FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA48.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

36registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ioflupane I-123 in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ioflupane I-123 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Idiopathic Parkinson's Progression and Dopamine Transporter SPECT

    NCT03531086 · start 2018-01-19

    Registered record
    Registry ID
    NCT03531086
    Conditions
    Parkinson Disease
    Interventions
    Ioflupane I 123
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-01-19
    Completion
    2021-09-01
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionIoflupane I 123
    PhaseNot recorded
    Registry statusCompleted

  • Diagnostic Imaging for Clear Cell Renal Cell Carcinoma

    NCT03185182 · start 2017-07-14

    Registered record
    Registry ID
    NCT03185182
    Conditions
    Clear Cell Renal Cell Carcinoma
    Interventions
    Ioflupane I123
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-07-14
    Completion
    2018-09-12
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClear Cell Renal Cell Carcinoma
    InterventionIoflupane I123
    PhasePhase 2
    Registry statusTerminated

  • A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

    NCT01950468 · start 2017-04

    Registered record
    Registry ID
    NCT01950468
    Conditions
    Parkinson's Syndrome
    Interventions
    NAV5001; DaTscan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2017-04
    Completion
    2018-03
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Syndrome
    InterventionNAV5001; DaTscan
    PhasePhase 3
    Registry statusWithdrawn

  • Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain

    NCT03058965 · start 2016-11-29

    Registered record
    Registry ID
    NCT03058965
    Conditions
    Alzheimer Disease; Healthy Volunteers; Progressive Supranuclear Palsy
    Interventions
    [18F]MNI-958; [18F]Florbetapir; DaTscan
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2016-11-29
    Completion
    2018-05-11
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Healthy Volunteers; Progressive Supranuclear Palsy
    Intervention[18F]MNI-958; [18F]Florbetapir; DaTscan
    PhaseEarly phase 1
    Registry statusCompleted

  • DAT SPECT and Procedural Motor Skills in Parkinson's Disease

    NCT03076307 · start 2016-10-18

    Registered record
    Registry ID
    NCT03076307
    Conditions
    Parkinson Disease
    Interventions
    Procedural Motor Skills with mirror-drawing of figures
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-10-18
    Completion
    2017-07-19
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionProcedural Motor Skills with mirror-drawing of figures
    PhaseNot applicable
    Registry statusCompleted

  • Compensation Mechanisms in Parkinson's Disease

    NCT02869945 · start 2016-09

    Registered record
    Registry ID
    NCT02869945
    Conditions
    Parkinson Disease
    Interventions
    Identification of COMT HH, COMT HL or COMT LL genes; Brain MRI with resting state scan; Brain MPET
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2016-09
    Completion
    2021-07-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionIdentification of COMT HH, COMT HL or COMT LL genes; Brain MRI with resting state scan; Brain MPET
    PhaseNot applicable
    Registry statusCompleted

  • Nigrosomal Iron Imaging in Parkinson's Disease

    NCT03022357 · start 2016-06

    Registered record
    Registry ID
    NCT03022357
    Conditions
    Parkinson Disease
    Interventions
    Patient assessment; DATScan; Orbital X-Ray; Magnetic Resonance Imaging (MRI)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2016-06
    Completion
    2019-05
    Enrolment
    145

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionPatient assessment; DATScan; Orbital X-Ray; Magnetic Resonance Imaging (MRI)
    PhaseNot recorded
    Registry statusUnknown

  • Systemic Synuclein Sampling Study (S4)

    NCT02572713 · start 2015-10

    Registered record
    Registry ID
    NCT02572713
    Conditions
    Parkinson's Disease
    Interventions
    Biofluid samplings; Tissue samplings; DaTSCAN™
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-10
    Completion
    2017-08-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionBiofluid samplings; Tissue samplings; DaTSCAN™
    PhaseNot recorded
    Registry statusCompleted

  • Validation of DaTscan for Detection of Parkinson Disease Related Disorders

    NCT02138682 · start 2014-07

    Registered record
    Registry ID
    NCT02138682
    Conditions
    Parkinson Disease; Movement Disorders
    Interventions
    l-123 Ioflupane
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2014-07
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Movement Disorders
    Interventionl-123 Ioflupane
    PhaseNot recorded
    Registry statusUnknown

  • Parkinson's Disease Biomarker Program

    NCT01767818 · start 2012-11

    Registered record
    Registry ID
    NCT01767818
    Conditions
    Parkinson's Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-11
    Completion
    2017-09-30
    Enrolment
    238

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls

    NCT01160263 · start 2012-10

    Registered record
    Registry ID
    NCT01160263
    Conditions
    Amyotrophic Lateral Sclerosis
    Interventions
    SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10
    Completion
    2014-10
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAmyotrophic Lateral Sclerosis
    InterventionSPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
    PhasePhase 3
    Registry statusCompleted

  • Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects

    NCT01788696 · start 2012-06

    Registered record
    Registry ID
    NCT01788696
    Conditions
    Parkinson Disease
    Interventions
    Group A - Early Imaging; Group B - Delayed Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-06
    Completion
    2015-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionGroup A - Early Imaging; Group B - Delayed Imaging
    PhasePhase 1
    Registry statusCompleted

  • DaTSCAN Imaging in Aging and Neurodegenerative Disease

    NCT01453127 · start 2011-10

    Registered record
    Registry ID
    NCT01453127
    Conditions
    Dementia; Parkinsonism; Mild Cognitive Impairment; REM Sleep Behavior Disorder
    Interventions
    I-123 Ioflupane solution injection prior to SPECT scan (DaTscan); Single photon emission computed tomography (SPECT) scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Enrolling by invitation
    Start
    2011-10
    Completion
    2026-12
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia; Parkinsonism; Mild Cognitive Impairment; REM Sleep Behavior Disorder
    InterventionI-123 Ioflupane solution injection prior to SPECT scan (DaTscan); Single photon emission computed tomography (SPECT) scan
    PhasePhase 4
    Registry statusEnrolling by invitation

  • Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression

    NCT01141023 · start 2010-06

    Registered record
    Registry ID
    NCT01141023
    Conditions
    Parkinson Disease
    Interventions
    DaTscan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-06
    Completion
    2020-06-30
    Enrolment
    952

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionDaTscan
    PhasePhase 2
    Registry statusCompleted

  • Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients' First Degree Relatives

    NCT01089270 · start 2010-03

    Registered record
    Registry ID
    NCT01089270
    Conditions
    Parkinson Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2010-03
    Completion
    Not recorded
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown